It has been approved by the European Medicines Agency for the treatment of adult vitreomacular traction and macular holes related to macular traction with a pore size ≤ 400 μm [170,171,172], implying the potential for targeting Gal3 in the treatment of retinal disease. Here, LGALS3 is linked to macular holes.